Pharmaceutical Investing ELAHERE® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian Cancers
Pharmaceutical Investing The One & Only BOTOX® Cosmetic Day Returns November 19 with the Biggest Celebration of the Year
Pharmaceutical Investing AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib in Adults and Adolescents with Vitiligo
Pharmaceutical Investing Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM
Pharmaceutical Investing The Confidence Project by BOTOX® Cosmetic Unveils This Year's Grant Recipients
Pharmaceutical Investing RINVOQ® Demonstrated Superiority Versus HUMIRA® for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
Pharmaceutical Investing U.S. Food and Drug Administration Approves Updated Indication Statement for RINVOQ® for the Treatment of Inflammatory Bowel Disease
Pharmaceutical Investing AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
Pharmaceutical Investing SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer
Pharmaceutical Investing AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA for the Treatment of Upper Limb Essential Tremor
Pharmaceutical Investing AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
